Get to know our clinical trials

Development and validation of a predictive model (PancreaDix) for the early diagnosis of pancreatic cancer based on molecular markers, imaging, and clinical information using Big Data tools through a multicenter observational study.

Imagen de la Dra. Maria Teresa Herráiz Bayod, especialista en Digestivo de la Clínica Universidad de Navarra. La Dra. Herráiz se dedica preferencialmente a la prevención y tratamiento de tumores digestivos.
Dr. Mª Teresa Herraiz Curriculum
Director Digestive Department
Navarre headquarters
Cancer Center
Gastrointestinal Cancer Area
Status
In recruitment
headquarters
Pamplona

Technical Summary

  • DEVELOPMENT AND VALIDATION OF A PREDICTIVE MODEL (PANCREADIX) FOR THE EARLY DIAGNOSIS OF PANCREATIC CANCER BASED ON MOLECULAR MARKERS, IMAGING, AND CLINICAL INFORMATION USING BIG DATA TOOLS THROUGH A MULTICENTER OBSERVATIONAL STUDY.
  • Code EudraCT: .
  • Protocol number: AMD-CPA-2024-02
  • Promoter: Advanced Marker Discovery - AMADIX
  • Molecule/Drug: PancreaDix

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION